Wanbury Limited stands as a prominent pharmaceutical company that has established itself as a key player in both the global Active Pharmaceutical Ingredients (API) market and the domestic branded formulations segment. Incorporated in 1988, Wanbury Ltd is in the business of pharmaceutical and related activities, including research. The company was formerly known as Pearl Organics Limited and changed its name to Wanbury Limited in 2004. Wanbury Limited was incorporated in 1988 and is headquartered in Navi Mumbai, India.
Wanbury Ltd is a pharmaceutical company with a significant presence in the API global market and domestic branded Formulations. It's majorly into Active Pharmaceutical Ingredient (API) Sales & Marketing in over 50 countries and Pan-India Formulation presence, offering API products in over 70 countries.
The company operates through two main business segments:
- API Division: The Company provides Metformin and Sertraline, among approximately 13 API products. Metformin is used for the treatment of type 2 diabetes and Sertraline is an anti-depressant. It manufactures Metformin with a capacity of over 8500 tons per year. The product portfolio also includes Diphenhydramine, Mefenamic Acid, Glucosamine, Methoxsalen, and Paroxetine.
- Formulations Segment: The company offers formulations for gynecology, orthopedics, hematinic, anti-diabetic, nutraceuticals, gastro intestinal, stroke surgery, antibiotics, cough and cold solutions, anti-inflammatory, analgesics, and general practitioner. It also provides API products for anti-diabetic, anti-analgesic, anti-depressant, anti-histaminic, anti-inflammatory, anti-arthritis, anti-thrombotic, anti-epileptic, and anti-hypertensive therapeutic areas.
Wanbury has built a strong international presence through strategic subsidiaries, including Wanbury Holdings B. V. (Netherland), Wanbury Global FZE (UAE), Ningxia Wanbury Fine Chemicals Co. Ltd. (China) and Cantabria Pharma S. L. (Spain). This global network enables the company to serve markets across multiple continents.
The company has demonstrated strong financial performance in recent years. Wanbury's audited FY25 results reported a revenue of Rs 599.5 Cr and a profit of Rs 30.5 Cr. This represents significant growth momentum for the company.
For the full fiscal year 2024, Wanbury reported a net profit of Rs. 30.4 crore, a remarkable turnaround from the previous year's loss of Rs. 10.4 crore. The company demonstrated a notable 15% year-over-year growth in revenue, driven primarily by robust sales of key products such as Metformin and Sertraline. Net profit for Q4FY24 surged by an impressive 696% compared to the same quarter last year, reaching Rs. 8.3 crore.
- Market Capitalization: ₹999 Crore (as of recent data)
- Operating Revenue (TTM): ₹565.16 Crore
- Annual Revenue Growth: 16%
- Pre-tax Margin: 10%
- Return on Equity (ROE): 70.0% (FY25), 200% (TTM)
- Return on Capital Employed (ROCE): 34.9%
- P/E Ratio: 32.7
- Book Value: ₹18.1
- 52-week High/Low: ₹325.00 / ₹132.55
- Promoter Holding: 39.76% (March 2025)
- Promoters Pledged Holding: 76.7%
Wanbury has achieved significant regulatory milestones, underscoring its commitment to quality and compliance. The company's Tanuku facility was granted an ANVISA GMP certificate, valid till January 2027, after a zero-observation inspection. This demonstrates manufacturing excellence and adherence to international quality standards.
The company has also successfully cleared important regulatory inspections, with USFDA and ANVISA inspections cleared as part of its recent achievements. These regulatory approvals are crucial for maintaining and expanding the company's global market presence.
Wanbury has undertaken several strategic initiatives to strengthen its financial position and operational capabilities. The company recently issued Rs 175 Cr NCDs and refinanced existing debt, securing a significantly reduced interest rate of 12.5% per annum on up to Rs 150 crore. This covers Rs 90 crore owed to NEO AIF & associates and Rs 60 crore owed to other lenders. The remaining funds will be used for working capital and capital expenditure to support the company's growth, with repayment structured over 5 years.
Wanbury has established itself as a significant player in the pharmaceutical industry, particularly in the API segment. The company manufactures and markets pharmaceutical products, focusing on active pharmaceutical ingredients (APIs) and formulations. It serves global markets with a range of therapeutic solutions in areas like anti-diabetics, pain management, and gastrointestinal treatments. The company's stock has shown strong performance, with a 285.24% increase on BSE over the last 3 years.
As of March 2025, Promoter holding in Wanbury Ltd has marginally decreased to 39.76 per cent from 39.79 per cent as of June 2024. It is worth noting that Promoters have pledged 76.7% of their holding.
Wanbury Limited represents a compelling investment opportunity in the pharmaceutical sector, with its diversified business model spanning both API manufacturing and formulations, strong international presence, and demonstrated financial performance improvements. The company's commitment to quality, regulatory compliance, and strategic growth initiatives positions it well for continued expansion in the global pharmaceutical market.
